Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
FATE
FATE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FATE News
Fate Therapeutics Appoints New Board Member
5d ago
Newsfilter
GT Biopharma Advances NK Cell Therapy with TriKE Platform
Jun 12 2026
Globenewswire
GT Biopharma Advances NK Cell Therapy with TriKE Platform
Jun 12 2026
Newsfilter
GT Biopharma Advances Three Drug Candidates into Clinical Trials
Jun 08 2026
Globenewswire
GT Biopharma Advances Three Cancer Drug Candidates into Clinical Trials
Jun 08 2026
Newsfilter
FT819 CAR T-Cell Therapy Expands Patient Access
Jun 04 2026
Newsfilter
FT836 Shows Significant Lesion Reduction in Metastatic Colorectal Cancer
Jun 01 2026
Newsfilter
Analysis of Fate Therapeutics' Cash Burn Risks
May 30 2026
Yahoo Finance
GT Biopharma: Three Drugs Enter Human Trials
May 29 2026
PRnewswire
GT Biopharma Advances Three Drug Candidates in Clinical Trials
May 29 2026
Newsfilter
Fate Therapeutics Unveils CAR T-Cell Therapy Data at Major Conferences
May 21 2026
Newsfilter
Cell Therapies Propel Growth in Anti-Aging Market
May 20 2026
Newsfilter
Cell Therapies Propel Growth in Anti-Aging Market
May 20 2026
PRnewswire
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
May 19 2026
Newsfilter
Fate Therapeutics Q1 Earnings Report Analysis
May 13 2026
seekingalpha
FT819 Achieves Significant Clinical Responses in Active SLE Patients Without Conditioning Chemotherapy
May 11 2026
Newsfilter
Show More News
